Akebia Therapeutics (AKBA) Preferred Stock Liabilities (2013)
Akebia Therapeutics (AKBA) posted quarterly Preferred Stock Liabilities of $157.8 million for Q4 2013.
Akebia Therapeutics (AKBA) Preferred Stock Liabilities (2013) Analysis & Trends
Akebia Therapeutics (AKBA) has reported Preferred Stock Liabilities for 1 consecutive years, with $157.8 million the latest figure, recorded in Q4 2013.
- In Q4 2013, Preferred Stock Liabilities changed N/A year-over-year to $157.8 million; the TTM figure through Dec 2013 stood at $157.8 million (changed N/A YoY), while the FY2013 annual figure was $157.8 million, up 696.46% from the prior year.
- Preferred Stock Liabilities steadied at $157.8 million in Q4 2013 per AKBA's latest filing.
- Across five years, Preferred Stock Liabilities topped out at $157.8 million in Q4 2013 and bottomed at $157.8 million in Q4 2013.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Akebia Therapeutics | 249.25 Mn | 93.70 Mn | 38.70 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2013 | 157.83 Mn |